To confirm whether any drugs have targeted these curated AD-associated risk genes in Phase 1, 2 or 3 clinical trials for AD (called clinical AD drug targets, which include 34, 109, and 49 genes for Phases 1, 2, and 3 trials, respectively) (Cummings et al., 2019), we searched for gene overlaps between the GWAS gene list and the clinical AD drug targets, which produced five gene matches (TREM2, CD33, CHRNA2, PRSS8, and ACE) (Supplementary Table S2I). This evidence concerns the gene CHRNA2 and Alzheimer disease.